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Abstract
The optimal treatment strategy for patients with symptomatic hypertrophic obstructive cardio-
myopathy (HOCM) and end-stage liver disease (ESLD) is not well defined. Although medical
management is the accepted first line treatment, patients who are unresponsive to medication
require further interventions. Since ESLD patients have a high operative risk for surgical
myomectomy, alcohol septal ablation (ASA) emerges as a good alternative in these cases. The
timing of ASA in relation to liver transplantation is still unclear. We report here on the first
case of an orthotopic liver transplant-recipient undergoing ASA and the second of a cirrhotic
patient requiring ASA as a bridge to liver transplantation. Both patients had a good clinical
outcome and we argue that ASA in HOCM patients should be driven by symptom onset, and
that in the asymptomatic patient it can be safely deferred until after liver transplantation.
(Cardiol J 2008; 15: 74–79)




(HOCM) is a heterogeneous disorder, affecting
patients of all ages. It has a diverse clinical course
where some individuals remain asymptomatic
throughout life while others develop severe symp-
toms of heart failure, angina or syncope, and a mi-
nority present with sudden cardiac death. The left
ventricular outflow gradient is an independent pre-
dictor of HOCM-related death, progression to New
York Heart Association (NYHA) class III or IV heart
failure, and for death from heart failure or stroke
when it exceeds 30 mm Hg [1]. The optimal treat-
ment strategy for patients with symptomatic HOCM
and end-stage liver disease (ESLD) is not well defined.
ESLD patients have a high operative risk for surgical
myomectomy [2–5]. Alcohol septal ablation (ASA)
emerges as a good alternative to surgical myomecto-
my in these patients. The presence of symptomatic
HOCM is considered a contraindication for liver trans-
plantation in ESLD [6]. We report on two patients with
ESLD who underwent ASA, the first secondary to
worsening symptoms after liver transplant and the
second as a bridge to liver transplantation.
Case No. 1
A 58-year-old white female with HOCM and
ESLD secondary to longstanding autoimmune hep-
atitis presented for evaluation for liver transplan-
tation due to deteriorating hepatic function. She was
relatively asymptomatic from the cardiac standpoint
with no angina, heart failure or syncopal symptoms.
On physical examination, she was jaundiced but had
no jugular venous distention (JVD). The carotid
upstrokes were bifid, the first and second heart
sounds were normal, and a fourth heart sound was
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present. A 3/6 mid- to late-peaking outflow murmur
was heard across the precordium. Lungs were clear,
and there was no peripheral oedema. Electrocardio-
graphy showed a left bundle branch block and left
ventricular hypertrophy. A transthoracic echocardi-
ogram (TTE) showed a left ventricular outflow tract
(LVOT) gradient of 91 mm Hg, interventricular sep-
tum (IVS) of 15 mm, left ventricular posterior wall
(LVPW) of 14 mm and mild systolic anterior mo-
tion (SAM). Cardiac catheterization showed a LVOT
gradient of 60 mm Hg at rest, a hyperdynamic left
ventricle with a left ventricular ejection fraction
(LVEF) of 80%, and angiographically normal-ap-
pearing coronaries. Since her cardiac symptomatol-
ogy was stable on beta-blockers, she was consid-
ered to be a suitable candidate for orthotopic liver
transplantation, which she underwent with no ad-
verse cardiovascular events. Within one year of her
liver transplantation, she developed lower extrem-
ity oedema and angina despite adequate medical
therapy. TTE then showed an LVOT gradient of 99
mm Hg, IVS of 20 mm and LVPW of 16 mm. Surgi-
cal myomectomy versus ASA was discussed with
the patient, who opted for ASA. This was performed
with an infusion of 3 cc of 100% ethanol into the first
and second septal arteries under myocardial con-
trast echocardiography and fluoroscopic guidance.
The left ventricle/aorta (LV/Ao) gradient was 100
mm Hg at rest and 200 mm Hg after a premature
ventricular contraction (PVC), but decreased to 10
mm Hg and 30 mm Hg at rest and after a PVC, re-
spectively, post-ablation (Fig. 1). She developed
complete heart block on the second day after the
procedure and required a permanent pacemaker.
She became symptom free post ASA and remained
without angina or heart failure symptoms one year
later. TTE then showed reduction of the IVS and
LVPW diameters to 16 and 15 mm, respectively,
with a preserved LVEF and no detectable LVOT
gradient.
Case No. 2
A 51-year-old white male with ESLD second-
ary to alcoholism and hepatitis C infection was en-
rolled on the liver transplantation waiting list after
he quit drinking. During his pre-transplant evalua-
tion process, he noted chest tightness, dyspnea on
exertion and near syncope. On examination, he was
jaundiced and had evidence of JVD. His cardiac
exam was relevant for a grade II/VI systolic ejec-
tion murmur with a diastolic component and a pos-
itive fourth heart sound. The lungs were clear, and
he had mild ascites with 1+ pitting oedema of the
ankles and feet. Electrocardiography showed non-
specific T wave changes. TTE revealed asymmetric
left ventricular hypertrophy (LVH), with IVS of
21 mm, LVPW of 13 mm, a resting LVOT obstruc-
tion with a peak gradient of 64 mm Hg at rest and
102 mm Hg with provocation, mild SAM of anterior
mitral leaflet (Fig. 2) and moderate mitral incom-
petence with a normal LVEF, all consistent with
HOCM. Cardiac catheterization documented mid-
cavity obliteration with an LV-Ao gradient of
120 mm during sinus rhythm and 220 mm Hg post-PVC,
as well as grade II mitral regurgitation (Fig. 3).
Figure 1. Assessment of left ventricular outflow gradient of patient 1 with hypertrophic cardiomyopathy before (A)
and after (B) alcohol septal ablation using cardiac catheterization. Significant improvement of the gradient is visuali-
zed (B). Left ventricular pressure tracing in grey colour and aortic pressure tracing in white. The arrow in A and B
denotes post premature ventricular contraction pressure gradients.
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He continued to be symptomatic despite treatment
with beta-blockers. He was deemed high risk for
liver transplantation due to his symptomatic HOCM
and high risk for surgical myomectomy due to his
ESLD. Under TTE and fluoroscopy guidance, 4 ml
of 100% ethanol was injected into the first septal
artery. The LV-Ao gradient fell to 3 mm Hg post
ablation (Fig. 3). The patient had a good recovery
with improvement of his dyspnea and chest pain.
Repeat echocardiography six months later showed
an improvement of the LVOT resting gradient at
27 mm Hg and amelioration of both IVS and LVPW
diameters (15 mm and 13 mm, respectively) with
no signs of SAM of the anterior mitral leaflet. The
patient underwent orthotopic liver transplantation
in November of 2005 without major complications.
One year after his transplant the patient continued
to report no dyspnea or angina even with exertion.
Discussion
Hypertrophic cardiomyopathy is a complex
genetic cardiac disease, diagnosed principally with
TTE by demonstrating LVH, wall thickness of at
least 15 mm in adults, typically asymmetric, in the
absence of another cardiac or systemic disease ca-
pable of producing a similar degree of hypertrophy
(e.g., hypertension or aortic stenosis) [7]. HOCM
refers to the presence of a dynamic LVOT obstruc-
tion usually caused by SAM of the anterior mitral
valve leaflet and projection of the hypertrophied
interventricular septum into the outflow tract in
systole. Management is aimed at alleviating symp-
toms of heart failure, angina and syncope on one
hand, and preventing sudden death in high-risk in-
dividuals on the other. Medical therapy is the first
line of treatment and consists of beta-blockers, cal-
cium channel antagonists and disopyramide, solely
or in combination. Surgical septal myomectomy or
more recently ASA are recommended for the small
subgroup of patients (5%) who have both a large
outflow gradient (usually > 50 mm Hg at rest or on
provocation) and moderate to severe heart failure
or angina symptoms unresponsive to maximal med-
ical therapy [7]. Historically, surgical septal myo-
mectomy has been the “gold standard” treatment
for HOCM patients refractory to medical therapy,
perhaps due to more than 40 years of experience,
a relatively low perioperative mortality rate (1–3%),
high success rate with clinical improvement report-
ed in up to 90% of patients, and excellent long-term
survival [7, 8]. ASA emerged in 1995 [9] as an al-
ternative procedure to surgery and has since grown
quickly in popularity to the point that it is estimat-
ed that more ASAs have been performed since its
introduction than the total number of surgical myo-
mectomies performed during the last 45 years [8].
Studies have shown that ASA is as effective as sur-
gery in improving symptoms and reducing LVOT
gradient in the short- and intermediate-term; how-
ever, there is still a lack of data regarding long-term
follow up, which is the main argument of its detrac-
tors [10]. At present, there is no general agreement
between cardiologists and surgeons regarding
which procedure should be the first-line interven-
tion for most HOCM patients after medical treat-
ment failure. Patients with advanced age or sig-
nificant comorbidities and/or relative contraindi-
cations to surgery are often considered good
candidates for ASA.
ESLD patients undergoing general anesthesia
and non-hepatic surgery are at increased risk for
perioperative complications, with an overall 30-day
Figure 2. Transthoracic echocardiography of patient 2
with hypertrophic cardiomyopathy before alcohol sep-
tal ablation. A. 5-chamber view showing hypertrophied
interventricular septum and systolic anterior motion
(SAM) of the anterior mitral valve leaflet (white arrow);
B. M-mode across the mitral valve showing SAM of the
anterior mitral valve leaflet (black arrow).
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mortality rate ranging between 11% and 17% [11–13].
The surgical prognosis correlates with the severi-
ty of cirrhosis. In one study, patients with Child
class A, B and C had 1-month mortality rates of
3.6%, 31.7% and 54.5%, respectively [11]. The clin-
ical outcomes are even poorer after cardiac surgery
in patients with ESLD, with mortality rates of 50%
to 80% in class B patients [2, 4, 5, 11] and 100% in
class C patients [2, 5]. The difference in mortality
between cardiac and non-cardiac surgery in patients
with ESLD stems from the use of cardiopulmonary
bypass, a known trigger for the production and re-
lease of several vasoactive substances and cytotoxic
chemicals that are responsible for much of the mor-
bidity associated with open heart surgery [14, 15].
These findings have been verified by the very re-
cent report by Filsoufi et al. [16] in which opera-
tive and 1-year mortality as well as postoperative
complications were directly related to the Child
class in cirrhotic patients who underwent cardiac
surgery, and, significantly, no operative mortality
occurred in patients who had cardiac surgery with-
out the use of cardiopulmonary bypass.
When this prognostic data is considered, it be-
comes apparent that patients with cirrhosis, whose
diseases are advanced enough for them to be consid-
ered as liver transplant candidates, are absolute non-
candidates for surgical septal myomectomy. ASA has
evolved as a very attractive treatment modality in this
high-risk surgical group. However, it still remains
uncertain whether patients with HOCM should un-
dergo ASA prior to or after liver transplantation.
On the other hand, little is known about the risk
of general anesthesia and major non-cardiac surgery
in patients with HOCM. In this regard, the incidence
of adverse cardiovascular events such as heart failure,
Figure 3. Assessment of left ventricular outflow gradient of patient 2 with hypertrophic cardiomyopathy before (A, B)
and after (C, D) alcohol septal ablation using Doppler echocardiography (A, C) and cardiac catheterization (B, D).
Significant improvement of the gradient is noted. Left ventricular pressure tracing in grey colour and aortic pressure
tracing in white.
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ischemia and arrhythmias, varied from 16% to 44%
in the studies reviewed [17–20], with a strikingly
low rate of postoperative death and myocardial inf-
arction (near 0%) in HOCM patients undergoing
non-cardiac surgery [18–20]. Perioperative cardio-
vascular compromise is the main concern when
performing a major surgery, such as liver transplan-
tation, on patients with HOCM. However, most of
these complications are transitory and treatable,
and studies failed to report increased postsurgical
mortality rates in these individuals. Moreover,
three case reports demonstrated no perioperative
cardiovascular events in HOCM patients receiving
orthotopic liver transplantation, analogous to our
first case [21, 22]. The other option is to perform
ASA prior to surgery in order to avoid these report-
ed potential perioperative complications [17–20],
with the possible downside of delaying surgery. It is
still uncertain whether improvement of the LVOT
by ASA will translate into reduction of the aforemen-
tioned perioperative adverse cardiovascular events.
We report here on the first case, to the best of
our knowledge, of an orthotopic liver transplant
recipient undergoing ASA and the second [23] of
a cirrhotic patient requiring ASA prior to liver
transplantation. Our first patient with cirrhosis and
asymptomatic HOCM had an uneventful liver trans-
plantation but required ASA 1.5 years post-trans-
plant due to worsening symptoms. The second pa-
tient had ASA performed 15 months before liver
transplantation, which facilitated his enlistment on
the transplant list. In both scenarios, the clinical
outcome was favourable and the decision to perform
ASA was mainly driven by symptomatic HOCM.
Currently, there is no strong evidence to support
either approach.
In conclusion, ASA in ESLD patients with
HOCM is safe and effective. ASA can be performed
as a bridge to liver transplantation in symptomatic
patients. Patients with asymptomatic HOCM can
safely undergo liver transplantation and deferring
ASA until symptom development.
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